Methylphenidate is primarily used for attention deficit hyperactivity disorder (ADHD) 
INTRODUCTION

Methylphenidate (N06B A04) is primarily used in South
Africa for narcolepsy and attention deficit hyperactivity disorder (ADHD) in children (SAMF, 2003:449) . According to the British National Formulary (BNF, 2003:198) methylphenidate is indicated as part of a comprehensive treatment programme for ADHD when remedial measures alone prove insufficient (the BNF therefore does not mention narcolepsy as an indication for methylphenidate). ADHD is a common yet controversial syndrome of unknown aetiology characterised by varying degrees of inappropriate hyperactivity, impulsivity and inattention (Markowitz & DeVane, 2000:4) . International studies have yielded ADHD prevalence rates of between 1.7% and 16%, dependent on the population assessed and the criteria applied (Goldman, Genel, Bezman & Slanetz, 1998 :1102 Markowitz & DeVane, 2000:5) . Epidemiologic studies using standardised diagnostic criteria suggest that 3% to 6% of the schoolaged population may have ADHD (Goldman et al. 1998 (Goldman et al. :1100 . Some studies have suggested a somewhat lower prevalence, but others, particularly those using newer, broader criteria, yield prevalence rates well above 6% (Goldman et al. 1998 (Goldman et al. :1106 . These studies have been conducted in a number of different countries and encompass a range of racial and socio-economic backgrounds in the populations examined (Goldman et al. 1998 (Goldman et al. :1106 .
There are more boys with diagnosed ADHD than girls, with male to female ratios ranging from 4:1 to 6:1 (Berry, Shaywitz & Shaywitz, 1985:801) . Some studies suggest that ADHD is diagnosed three to nine times more often in boys than in girls (Markowitz & DeVane, 2000:5) .
Various studies confirm the increasing trend for girls to receive pharmacotherapy for ADHD (Robison, Sclar, Skaer & Galin, 1999:216) and that girls are now being diagnosed more often than in the past (Markowitz & DeVane, 2000:5) . Reasons for this gender discrepancy are not clear, but some researchers suggested selective referral bias in the past since girls may have primarily inattentive and cognitive problems and less of the aggressive/impulsive conduct symptomatology which leads to earlier referral (Cantwell, 1996:978; Baumgaertel, Wolraich & Dietrich, 1995:629-638) . It has been stated that the number of prescription orders written for females has increased disproportionately compared with that of males, and although ADHD exists in adults as well as children, the adult form affects females more often than males (Wick, 1993:52) .
Although various medications have been assessed for the treatment of ADHD, the psychostimulants (methylphenidate, dextroamphetamine, mixed amphetamine salts and pemoline) remain the drugs of choice for treating ADHD (Elia, Ambrosini & Rapoport, 1999: 780-788; Goldman et al. 1998 Goldman et al. :1103 . However, their role and indications remain controversial. Stimulants have been used for almost 50 years, although the exact mechanism of action is still unknown (Wick, 1993:52) . Methylphenidate, created in 1955, accounted for more than 90% of stimulant use in ADHD in the United States of America (USA) in the late 1990s (Goldman et al. 1998 (Goldman et al. :1103 . The National Institute for Clinical Excellence (NICE) has recommended (October 2000) that methylphenidate should be used as part of a comprehensive treatment programme for children and adolescents with a diagnosis of severe ADHD, and that treatment should be initiated by a specialist in ADHD (BNF, 2003:197) . Methylphenidate also remains the mainstay for the pharmacological management of ADHD in South Africa.
Methylphenidate is a dopamine agonist and is readily absorbed orally, with a half-life of one to two hours (SAMF, 2003:449) . The exact percentage of people in South Africa receiving methylphenidate is unknown.
Sales figures, however, indicate that there has been a steady increase in the use of methylphenidate (Crutchley & Temlett, 1999 :1076 . A survey conducted in the Pinetown municipal area of KwaZulu-Natal, South Africa, in 1991 indicated that 1.65% of all learners were on methylphenidate (Crutchley & Temlett, 1999 :1076 .
The ratio of boys to girls on methylphenidate was 9 to 1, and the age at which treatment was begun ranged from two to eleven years, with an average age of 7.6 years (Crutchley & Temlett, 1999 :1076 . A study conducted in North Carolina, USA, found that 15% of boys in grades 1 to 5 had received an ADHD diagnosis while 5% of girls were diagnosed with ADHD (Attention Deficit Hyperactivity Disorder, 2004:2) . In addition, three times as many boys as girls take medication to treat the condition (Attention Deficit Hyperactivity Disorder, 2004 :2).
The long-term safety of stimulant treatment must be considered in the treatment of ADHD. Three areas that Furthermore, the abuse potential of stimulant medication must be considered. Stimulant medications are regarded as drugs of abuse owing to their dependenceproducing liability and concerns are therefore increasing that children and adolescents treated with stimulant medication may start abusing them and that their use may serve as a gateway to other illicit drugs (Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults, 2002:45S). The fact that prescribed stimulants have a limited ability to induce euphoria by the oral route, as well as the fact that cocaine is mentioned 40 times more often than methylphenidate in emergency room mentions in the USA (Goldman et al. 1998) Although pharmacotherapy alone is highly effective for short-term symptomatic and academic improvement in ADHD (Goldman et al. 1998 (Goldman et al. :1103 , it has not yet been shown to improve the long-term outcome for any domain of functioning such as classroom behaviour, learning or impulsivity. Optimal treatment of ADHD involves an individualised plan based on any co-morbidity as well as child and family preferences. This treatment generally will include pharmacotherapy along with adjunctive psychoeducation, behavioural therapy, environmental changes, and at times, supportive psychotherapy of the child, the family or both (Goldman et al. 1998 (Goldman et al. :1106 .
There is an increased focus in the lay and medical press in South Africa on the use of methylphenidate, which suggests that more detailed studies are needed to in- are especially of concern in chronic stimulant treatment are the effects on growth, tics and cardiovascular parameters (Spencer, 2003) . Firstly, the stimulant most likely to cause growth retardation is dexamphetamine (Attention Deficit Hyperactivity Disorder, 2004:16) . Although growth is not generally affected by methylphenidate it remains advisable to monitor growth during treatment (BNF, 2003:197) . It is especially recommended to monitor growth in children (both height and weight gain) where doses of methylphenidate exceed 30 mg/ day for prolonged periods (SAMF, 2003:450) . Drug holidays over weekends and during school holidays are often used in an attempt to minimise growth suppression (Attention Deficit Hyperactivity Disorder, 2004:16) .
In one American study, growth deficits in height and weight were examined in 124 ADHD male children and adolescents and 109 controls using appropriate correction by age and parental height measures (Spencer, Biederman, Harding, O'Donnell, Faraone & Wilens, 1996 :1460 . Small but significant differences in height (2.1 cm age-corrected) were identified between ADHD children and controls. However, height deficits were evident in early, but not late-adolescent patients with ADHD and were unrelated to the use of psychotropic medication. Until more is known, a small minority of ADHD children may have delays in growth and it is therefore advisable to monitor children on stimulants for growth (Spencer, 2003) .
Secondly, the potential for developing tics is another adverse effect of concern and controversy in the treatment of ADHD with stimulants. Evidence which suggests a genetic relationship between ADHD and Tourette's syndrome complicates this issue (Attention Deficit Hyperactivity Disorder, 2004:16) . Although the incidence of tics is rare, some individual patients on stimulants may experience a significant worsening of tics and health care practitioners should carefully monitor the course of stimulant-treated individuals for any persistent exacerbations of a tic disorder (Spencer, 2003) .
Thirdly, short-term studies all show small, clinically insignificant changes in blood pressure and heart rate in children with ADHD (Spencer, 2003) . It is recommended that the effect of stimulants on cardiovascular parameters nonetheless be monitored initially, with less frequent monitoring over time.
role players to compare South African prescribing patterns to those of other countries, but also the fact that major social changes have occurred in South Africa in recent years. These changes may have impacted on the emotional, social and psychological aspects in the upbringing and development of children and adolescents, which may (or may not) have increased the prevalence of behavioural disorders, such as ADHD.
The primary aim of the study was therefore to investigate the prescribing patterns of methylphenidate in a private sector, medical aid patient population in South Africa by means of a drug utilisation study and to compare the results with previous studies.
SUBJECTS AND METHODS
The study can be classified as an exposure cohort drug utilisation study. Data for the study were obtained from therefore not included in the study. It must also be noted that only patients who belonged to a private medical aid scheme in South Africa were included in this study.
Only approximately 18% of the South African population belonged to a private medical aid scheme (Central Statistical Service, 1996) . The rest of the patients were range for the age of all patients was 9 to 15 years (females 9 to 21.5 years, and males 9 to 15 years).
In a study conducted on a different South African patient population in 1996 on 96 patients who were prescribed methylphenidate, the average age of patients was 14.4 years, 88.5% of patients were under the age of 20 years and 75.0% of patients were males (Truter & Kotze, 2000:S42-S43) . In another South African study on methylphenidate prescribing patterns in 2002 (Truter, 2004:96) , similar results were obtained, namely 41.5%
of the 106 patients were between the ages of 10 and 19 years, the average age of patients was 14.6 years and 75.6% of patients were males.
Prescribing frequency of methylphenidate
The 115 patients received 455 prescriptions for methylphenidate during 2002. Patients therefore received on served by the state or public health sector for which no or limited data are available. 
RESULTS
Demographic characteristics of patients
Dosage forms and dosages of methylphenidate prescribed
Two-thirds of all prescriptions (67.3%) were for methylphenidate 10 mg (the innovator product), 20.7% were for the 20 mg slow-release innovator product and the rest were prescriptions for the recently introduced 10 mg generic equivalent tablet (see Table 3 ). Table 4 .
METHYLPHENIDATE NUMBER OF PRESCRIPTIONS PERCENTAGE DOSAGE FORM FEMALES MALES TOTAL (%)
Disorder of Childhood".
As can be seen in Table 4 , the patients over 30 years received methylphenidate in higher average PDDs than the younger patients. Most of these patients were prescribed methylphenidate 10 mg tablets, with only three patients receiving methylphenidate slow-release tablets in dosage strength of 20 mg. The higher dose in older patients is probably directly related to their higher body weight (body weight and length were not available in the database).
Other prescribing parameters of methylphenidate
Proportionately more prescriptions (44.4%) were Most prescriptions were obtained by patients from retail or community pharmacies, followed by general practitioners who dispensed medicine (dispensing doctors). The dose of methylphenidate for children under six years of age has not been established (SAMF, 2003:450; MIMS, 2002) . Four patients in this study were younger than six years. They all received methylphenidate in a dose of 10 mg per day. Three of them only received methylphenidate once, while the other patient (a fiveyear-old boy) received eight prescriptions during the year and all on the chronic plan of the medical aid scheme. This boy was diagnosed with "Attention Deficit
NUMBER OF NUMBER OF PATIENTS PERCENTAGE PRESCRIPTIONS FEMALES MALES BOTH GENDERS (%)
The number of prescriptions for methylphenidate per patient over the study period is depicted in Table 5 .
Nearly 30% of patients received six or more prescriptions for methylphenidate during the year, compared to only 11.5% in the other 2002 study (Truter, 2004) conducted on a different patient population. In this study, the median for females was 2.5 and for males 3.0. The observations in Table 5 
DISCUSSION
The over-diagnosis of ADHD in children, the long-term safety of stimulants, the possible link between the use of stimulants and drug abuse, and the increasing diagnosis of adult ADHD are just some of the controversies that have been debated by parents, educators, marketers of alternative medicines and health professionals in South Africa (Attention Deficit Hyperactivity Disorder, 2004:2) . It is recognised that the management of ADHD requires a multiple modality approach, combining psychosocial interventions and medical interventions (Cantwell, 1996:983 This finding is in line with the fact that ADHD occurs two to four times more commonly among boys than girls (Attention Deficit Hyperactivity Disorder, 2004:2) .
In the introduction, it was stated that international studies have yielded ADHD prevalence rates of between 1.7% and 16% (Goldman et al. 1998 (Goldman et al. :1102 Markowitz et al. 2000:5) . In this study, The results of this study were generally in agreement
